You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2024

CLINICAL TRIALS PROFILE FOR PANHEMATIN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for PANHEMATIN

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00467610 ↗ Phase 2, Open-Label, Multi-Dose Study of Panhematin in Patients With MDS Terminated H. Lundbeck A/S Phase 2 2007-05-01 This is a Phase II, open-label clinical trial examining the role of Panhematin® in patients with MDS. The objective of this study is to evaluate the safety and efficacy of Panhematin® (hematin for injection) in the treatment of adult patients (≥ 18 years of age) with low-risk MDS. The study will be conducted on an outpatient basis and will consist of the following: - A Screening Period (within 28 days of the Day 1) - Screening bone marrow aspiration and biopsy up to 60 days prior to receiving study medication - An 8-week Treatment Period (Days 1 through 4 of Week 1, and weekly visits during Weeks 2 through 8); partial and complete responders in any of the three cell lines may continue treatment for an additional 4 weeks - A 6-month Post treatment Follow-up Period (monthly clinic visits during Weeks 12 40)
NCT00467610 ↗ Phase 2, Open-Label, Multi-Dose Study of Panhematin in Patients With MDS Terminated Rush University Medical Center Phase 2 2007-05-01 This is a Phase II, open-label clinical trial examining the role of Panhematin® in patients with MDS. The objective of this study is to evaluate the safety and efficacy of Panhematin® (hematin for injection) in the treatment of adult patients (≥ 18 years of age) with low-risk MDS. The study will be conducted on an outpatient basis and will consist of the following: - A Screening Period (within 28 days of the Day 1) - Screening bone marrow aspiration and biopsy up to 60 days prior to receiving study medication - An 8-week Treatment Period (Days 1 through 4 of Week 1, and weekly visits during Weeks 2 through 8); partial and complete responders in any of the three cell lines may continue treatment for an additional 4 weeks - A 6-month Post treatment Follow-up Period (monthly clinic visits during Weeks 12 40)
NCT00882804 ↗ Hemin in Healthy Subjects Completed Mayo Clinic Phase 1 2009-02-01 This study is being done because we want to learn if hemin can increase the production of heme oxygenase 1. Heme oxygenase 1 (HO-1) is an enzyme which protects cells from physical, chemical, and biologic stress. Hemin is produced from red blood cells and is approved by the Food and Drug Administration for treating acute porphyria, which is an inherited condition caused by an enzyme deficiency.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for PANHEMATIN

Condition Name

Condition Name for PANHEMATIN
Intervention Trials
Healthy Volunteers 1
Hereditary Coproporphyria 1
Myelodysplastic Syndrome 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for PANHEMATIN
Intervention Trials
Porphyria, Erythropoietic 1
Porphyria, Acute Intermittent 1
Coproporphyria, Hereditary 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for PANHEMATIN

Trials by Country

Trials by Country for PANHEMATIN
Location Trials
United States 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for PANHEMATIN
Location Trials
Texas 1
Minnesota 1
Illinois 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for PANHEMATIN

Clinical Trial Phase

Clinical Trial Phase for PANHEMATIN
Clinical Trial Phase Trials
Phase 2 1
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for PANHEMATIN
Clinical Trial Phase Trials
Completed 1
Terminated 1
Active, not recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for PANHEMATIN

Sponsor Name

Sponsor Name for PANHEMATIN
Sponsor Trials
Rush University Medical Center 1
Mayo Clinic 1
The University of Texas Medical Branch, Galveston 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for PANHEMATIN
Sponsor Trials
Other 3
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.